Halosperm® is a kit to determine the degree of DNA fragmentation in human sperm, using sperm chromatin dispersion (SCD), a new clinical parameter that is probably responsible for most cases of male infertility of unknown origin.
The Halosperm® kit was developed in collaboration with J. Gosálvez, professor of molecular genetics at the Universidad Autónoma de Madrid, and J. L. Fernández and V. Goyanes, physicians in the Genetics Department at Hospital Universitario Juan Canalejo in A Coruña.
The method involves the denaturation and controlled lysis of the sample in an appropriate medium and can be used with both fresh and frozen samples
Sperm with intact DNA produce a dispersion halo as a result of the chromatin released from proteins that can be easily analyzed using fluorescence or bright field microscopy.
In contrast, sperm with fragmented DNA will not produce this halo. The technique is as easy as a routine leukocyte count.
Alternative techniques for determining the integrity of sperm DNA (SCSA, TUNNEL, ISNT, comet assay) are quite labour-intensive and expensive, which prevents their inclusion in the standard spermiogram used in clinical praxis
The analysis of the results of the Halosperm® kit can be performed by manually counting the halos under a bright field microscope.
The demand for semen studies and the use of assisted-reproduction techniques (artificial insemination, IVF, ICSI, etc.) have undergone dramatic growth.
This can be seen in the notable increase in the number of assisted-reproduction services and clinics in both the public and private spheres.
Routine semen analyses work by determining the concentration, morphology and motility of the sperm and are supplemented with certain functional tests, as well as the assessment of biochemical and seminal enzyme parameters (WHO, 1999).
Despite routine “screening,” it is impossible to determine the cause of infertility in around 30-50% of infertile males, a condition labelled as unexplained or idiopathic infertility.
Halosperm® was launched into the market in 2007, through a sublicense agreement signed between Fina Biotech and venture capital funded Halotech DNA S.L..The agreement entitled the Spanish company Halotech DNA to produce and sell on an exclusive and worldwide basis the Halosperm® kit. In 2010 the fund Suanfarma Biotech Fund sold its stake in Halotech DNA to Sexing Technologies, a North American company focused on gender identification of beef-cattle semen.
The customers and companies interested in the distribution and/or information of the product should contact Halotech DNA.
© 2013 Fina Biotech. Madrid. Tel +34 917 991 564 email@example.com